Shire International

Takeda (TSE:4502/NYSE:TAK) focuses on creating better health for people and a brighter future for the world. It aims to discover and deliver life-transforming treatments in core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. With its partners, Takeda aims to improve the patient experience and advance a new frontier of treatment options through a dynamic and diverse pipeline. Headquartered in Japan, the company has a commitment to patients, people and the planet. Takeda has employees in approximately 80 countries and regions.